Alpha particle radionuclides deliver precise, powerful radiation for targeted therapy
Radiotherapeutics

Selected Alpha Particle Emitting Radionuclides for Therapeutic Nuclear Medicine

Alpha particle emitting radionuclides are highly effective in delivering targeted radiation therapy for various cancers.

Selected Alpha Particle Emitting Radionuclides for Therapeutic Nuclear Medicine Read Post »

, , , , ,
PRRT targets tumours, delivering radiation while sparing surrounding healthy tissues
Radiotherapeutics

Peptide Receptor Radionuclide Therapy (PRRT): A Breakthrough in Treating Gastroenteropancreatic Neuroendocrine Tumours

Peptide Receptor Radionuclide Therapy utilises radiopharmaceuticals to target somatostatin receptor-expressing tumours, improving treatment outcomes significantly.

Peptide Receptor Radionuclide Therapy (PRRT): A Breakthrough in Treating Gastroenteropancreatic Neuroendocrine Tumours Read Post »

, ,
Innovative technologies enhance chronic disease management and improve patient outcomes
Medicine

Innovations in Chronic Disease Management: A New Frontier for Diabetes, Cardiovascular Disease, and Hypertension

Chronic disease management focuses on improving patient outcomes through personalised care, preventative measures, and technological advancements.

Innovations in Chronic Disease Management: A New Frontier for Diabetes, Cardiovascular Disease, and Hypertension Read Post »

, ,
brain scan using Pittsburgh Compound-B (PIB) PET imaging, highlighting amyloid plaques as bright spots within the brain
Nuclear Medicine Imaging

The Discovery and Development of Pittsburgh Compound-B (PIB): A Breakthrough in Alzheimer’s Disease Research

Pittsburgh Compound-B allows researchers to visualise amyloid plaques in the brain, aiding in Alzheimer’s disease diagnosis and study.

The Discovery and Development of Pittsburgh Compound-B (PIB): A Breakthrough in Alzheimer’s Disease Research Read Post »

, , ,
Scroll to Top